News Sentiment

BEAM sentiment intelligence

Beam Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 32.68 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-6.1% over one week, +12.6% over four weeks, trend active, and materially above fair value.

Latest direct headline Negative

Understanding the Setup: (BEAM) and Scalable Risk

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -6.1% Price reacting lower
Trend fit Trend active 12.6% over four weeks
Fair value 28.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 36
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
Stock Titan 8
Simply Wall Street 5
Investing.com 3
TradingView 3
simplywall.st 3
Stock Traders Daily 2
Trefis 2

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 11
Regulatory and legal 6
Analyst action 3
Balance sheet 3
Deals and strategy 3
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 60
Moomoo Direct company coverage

Beam Therapeutics(BEAM.US) 10% Shareholder Sells US$10.04 Million in Common Stock

A 10% shareholder of Beam Therapeutics (BEAM.US) recently sold a significant amount of common stock, totaling US$10.04 million. This transaction indicates a notable insider sale that could be of interest to investors tracking company performance.

Tone
Negative 31/100
Event
Market update
Published
29 Jun 2026 20:42
Source
Moomoo
Investing.com Direct company coverage

FMR LLC sells $10.04 million in Beam Therapeutics shares

FMR LLC, a major shareholder, recently sold Beam Therapeutics Inc. (NASDAQ:BEAM) shares worth approximately $10.04 million in late June, with sales occurring at weighted average prices between $35.12 and $35.26. The stock is trading near its 52-week high after a 107% gain over th

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 18:40
Source
Investing.com
Stock Titan Direct company coverage

FMR LLC (BEAM) trims Beam Therapeutics stake with 284,860-share open-market sale

FMR LLC, a significant owner of Beam Therapeutics Inc., reported trimming its stake by selling a total of 284,860 common shares through indirect open-market sales. These sales, executed via F-Prime Capital Partners Healthcare Fund V LP on June 25th and 26th, 2026, were valued at

Tone
Negative 32/100
Event
Deals and strategy
Published
29 Jun 2026 18:40
Source
Stock Titan
Simply Wall Street Direct company coverage

How FDA Clearance of BEAM-304’s Platform Trial for PKU May Impact Beam Therapeutics (BEAM) Investors

Beam Therapeutics announced FDA clearance for its BEAM-304 IND application for PKU, featuring a platform-style trial designed to test multiple base editors within a single clinical framework. While this strengthens Beam's in vivo liver editing story and provides a near-term clini

Tone
Positive 66/100
Event
Market update
Published
26 Jun 2026 22:10
Source
Simply Wall Street
TradingView Direct company coverage

Beam Therapeutics, Inc. Actuals & Estimates (NASDAQ:BEAM)

This article provides financial actuals and estimates for Beam Therapeutics Inc. (NASDAQ:BEAM), offering insights into its stock performance, analyst forecasts, and company financials. It details BEAM's current stock price, market capitalization, historical highs and lows, and up

Tone
Positive 66/100
Event
Analyst action
Published
26 Jun 2026 20:40
Source
TradingView
TradingView Direct company coverage

Beam Therapeutics, Inc. Actuals & Estimates (BMV:BEAM)

This article provides financial actuals and estimates for Beam Therapeutics, Inc. (BEAM) traded on the Mexican Stock Exchange (BMV). It details current stock price, historical performance, analyst forecasts, volatility, market capitalization, and upcoming earnings reports. Key fi

Tone
Positive 71/100
Event
Earnings
Published
26 Jun 2026 05:09
Source
TradingView
MarketBeat Direct company coverage

Beam Therapeutics (BEAM) Short Interest & Short Float | Updated Jun 2026

Beam Therapeutics (BEAM) saw its short interest increase by 31.94% to 28.31 million shares as of June 15, 2026, representing 28.60% of its public float. The short interest ratio or "days to cover" stands at 14.2, indicating strong pessimism among investors. This article provides

Tone
Negative 37/100
Event
Market update
Published
25 Jun 2026 20:11
Source
MarketBeat
TradingView Direct company coverage

Price to sales forward of Beam Therapeutics Inc. – NASDAQ:BEAM

The article focuses on the "Price to sales forward" metric for Beam Therapeutics Inc. (NASDAQ: BEAM). It provides a high-level view of this financial data point, indicating it is one of the many financial details available for the company on the TradingView platform. The content

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 19:41
Source
TradingView
Stock Traders Daily Direct company coverage

The Technical Signals Behind (BEAM) That Institutions Follow

This article analyzes Beam Therapeutics Inc. (NASDAQ: BEAM) through the lens of technical signals, highlighting strong sentiment across all horizons and an exceptional risk-reward setup targeting a 16.8% gain. It details three AI-generated trading strategies—Position, Momentum Br

Tone
Positive 72/100
Event
Market update
Published
25 Jun 2026 01:06
Source
Stock Traders Daily
Simply Wall Street Direct company coverage

Beam Therapeutics (BEAM) Could Be 78% Undervalued As FDA Clears BEAM 304

Beam Therapeutics (BEAM) is under investor focus after the FDA cleared its investigational new drug application for BEAM-304, an in vivo base editing therapy. The stock is currently trading at US$33.20, while a narrative fair value suggests it could be 77.9% undervalued at $150.

Tone
Positive 94/100
Event
Regulatory and legal
Published
24 Jun 2026 17:40
Source
Simply Wall Street